Plasmids pcDNA3.1-Cry1HA, pcDNA3.1-Bmal1, pcDNA-Per2V5 and Per1V5 were described previously (Kume et al., 1999) . The construction of the recombinant adenoviral vectors encoding various clock proteins was performed using the procedure of He et al. (He et al., 1998) . Briefly, Cry1-HA, Per1-V5, and Per2-V5 were cloned into Hind III/Eco RV, Hind III/Eco RV and Xho I/Eco RV of pAdTrack-CMV (a shuttle vector), respectively. The cloned pAdTrack-CMV shuttle vectors were subsequently cut with Pme I for linearization and then transformed into the E.coli BJ5183 strain along with the pAdEasy-1 adenoviral backbone vector to generate a complete adenoviral vector by in vivo recombination. For NLS-Cry1-HA adenovirus, cDNA encoding the protein was amplified by using 5'-Kpn I and SV40 large T antigen NLS primer (5'-ATCC GGT ACC ATG GAT CCA AAA AAG AAG AGA AAG GTA GGG GTG AAC GCC GTG CAC TGG-3' ) and 3'-Xba I and HA primer (5'-ATCC TCT AGA TCA AGC GTA ATC TGG AAC ATC GTA TGG GTA GTT ACT GCT CTG CCG-3') from the pcDNA-mCry1-HA plasmid. The PCR product was cloned into Kpn I/Xba I sites of the shuttle vector. For CBD-adenovirus, the C-terminal 101 amino acids of PER2 and V5 tag were cloned into XhoI/EcoRV in the shuttle vector. For BMAL1-adenovirus, 2XHA-Bmal1 (described below) was cloned into EcoRV in the
shuttle vector. Generation and purification of recombinant adenovirus in packaging cells (HEK293) was also performed according to He et al (He et al., 1998) . For Per2-LUC adenovirus, the ~1.5 kb fragment of Per2 promoter (pGL-2) (Yoo et al., 2005) was cloned into Xho I / Sac I sites of the pGL3-basic vector (Promega), and then Per2 promoter -luciferasepolyA from the vector was transferred into Kpn I / Sal I sites of pAd-Track (a promoterless shuttle vector) (He et al., 1998) . A complete adenoviral vector was generated as described above. For Bmal1-LUC adenovirus, the Bmal1 promoter and 3'-UTR (Nagoshi et al., 2004) and luciferase sequence from pGL3 basic vector (Promega) were cloned into Xho I and Eco RV sites of the pAd-Track vector. The luciferase in the original vector (Nagoshi et al., 2004) was replaced by luciferase from pGL3 basic vector to remove the Pac I site in the luciferase of the original vector. PCR primers to amplify the luciferase sequence from pGL3 basic were The original luciferase was replaced by the PCR fragment using Age I / Not I sites in the original vector (Nagoshi et al., 2004) . Bmal1-luciferase-3'UTR was cloned into the XhoI/EcoRV sites of the pAd-Track vector by PCR amplification/recombination. For Bmal1-PER2 adenovirus, Bmal1 3'-UTR and promoter along with Per2-V5 were cloned into Not I and Eco RV sites of the pAdTrack vector as follows. TheBmal1promoter was amplified by primers containing Not I and Xho I and cloned before N-terminus of Per2 in pcDNA-Per2-V5.
Forward 5'-ATCC GCGGCCGC GGG CTA CAA CAG AAC AAC TAA CCA CCC-3';
Reverse 5'-TAGG CTCGAG GGC TCG CTG CGA GCG CCC GCC CCC GC-3' 3'UTR of Bmal1 was amplified using primers containing Age I / Pme I sites and cloned after Cterminus of Per2 in the pcDNA.
Forward 5'-TAG TTA TTA CTA GCG CTA CC-3'
Reverse 5'-TAGG GTTTAAAC CCA GCC CCA GTA AAG GCT TTC TAG TGT-3'
The whole sequesnce was moved by Not I / Pme I and cloned into pAd-Track vector.
For Per2-PER2 adenovirus, the ~1.5 kb Per2 fragment was cloned into Not I and XhoI sites of pcDNA-Per2-V5-Bmal1 3' UTR, and then the whole sequence was transferred into Not I / Eco RV sites of the pAd-Track vector. The following primers were used to amplify the Per2 promoter.
Forward : 5' ATAAGAATGCGGCCGCCAAGCTTGCCTTCTCCAT 3' Reverse : 5' CCGCTCGAGTCGGACAAGATGCCTAACTAAT 3' Titers of CsCl density-gradient purified adenovirus were assessed by measuring DNA content.
Approximately, 1ml and 0.4 ml of 1X10 7 plaque forming units (pfu) /ml virus were used for infecting 60 mm and 35 mm dishes of MEFs, respectively. 1/2 of the titer was used for infecting COS7 cells. ~1X10 9 pfu of recombinant adenovirus was administered into a mouse by a systemic tail vein injection. pcDNA-FlagClock for binding assays was generated by inserting 3X FLAG tag sequence (Sigma, St. Louis, MO) at the N-terminus of pcDNA-Clock (Kume et al., 1999) . Similarly, 2XHA-Bmal1 was generated by inserting 2X HA tag sequence at the Nterminus of pcDNA-Bmal1 (Kume et al., 1999) . For Suppl. 
Generation of the tetO transgenic mice.
The tetO transgenes were constructed using Gateway technology (Invitrogen, Carlsbad, CA).
An Per2 cDNA (GenBank accession number AK122253) cloned in an attBpBC (a Gateway modified pBC SK+) vector was transferred into the pDONR221 and pTRE2ppDEST vectors respectively. The pTRE2ppDest destination vector was created to facilitate cloning of Gateway compatible cDNAs by modifying the pTRE2 vector (Clontech) by the addition of a Gateway destination cassette and four rare restriction endonuclease sites. The Gateway destination cassette contained attR1 sites and positive (Cm r ) and negative (ccdB) selection markers required for Gateway recombinant cloning. The rare 8-base-pair restriction endonucleases PmeI (New England BioLabs, Beverly, MA) and PacI (New England BioLabs) were mutated into the 5' end of the tetO sequence and the 3' end of the poly A. These sites were added to allow for easy removal of the tetO transgene from the vector backbone for injection into oocytes. The presence of the correct fragments in transformants was verified by digestion with BsrG1 (New England BioLabs), followed by gel electrophoresis on a 1% agarose gel. tetO constructs were purified on a cesium chloride gradient and excised with PmeI (New England BioLabs) and microinjected at a concentration of 1ng/uL into fertilized WT C57BL/6J mouse oocytes using standard transgenic methods. Transgenic mice were identified by PCR analysis of genomic DNA prepared from tail biopsies. Each individual transgenic mouse resulting from the microinjection was backcrossed to WT C57BL/6J mice to create the individual hemizygous tetO lines. Individual hemizygous tetO lines were then crossed to hemizygous animals containing Scg2:tTA (Hong et al., 2007) or CamK2:tTA (Mayford et al., 1996) to produce double transgenic as well as control animals. All animals were maintained in groups of five under standard conditions, with a 12 hour light and 12 hour dark (LD 12:12) cycle (lights on at 5:00 am) and free access to food and water.
Validation of transgenic lines.
Both tetO:Per2 transgenic lines were validated by in situ hybridization and quantitative PCR to determine Per2 expression from the transgene. Animals were euthanized by cervical dislocation at CT12 (peak of Per2 RNA) in DD. The in situ hybridization was performed with 20µm coronal sections encompassing the SCN, as previously described by Sangoram et al. (Sangoram et al., 1998) . The Per2 riboprobe was designed from nucleotides 243-705 of accession number AF035830. The relative expression was quantified using NIH "Image" software version 1.34s on a Macintosh computer as described by Panda et al. (Panda et al., 2002) Quantitative PCR was preformed on mRNA isolated from the cerebellum as previously described in the Applied Biosystems (Foster City, CA) Guide to Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR with the following primers:
Brain, olfactory bulbs and liver were collected from control (tetO:Per2 L2) and double transgenic mice on the 2 nd day in DD. SCN were punched out from ~1 mm coronal section and pooled from 5 mice as described previously (Chen et al., 2008) . Other tissues used for immunoblots were from one of the 5 mice.
Circadian activity analysis.
Free running period and relative power in the circadian range were calculated from the last 20 days in DD, dox, and H2O. Free running period was calculated using a Chi-square periodogram with a six minute resolution between hours 10 and 36 (ClockLab). The relative power of the circadian spectrum from 18-30 hours was determined from a normalized Fast
Fourier transform using a Blackman-Harris window (ClockLab). The period and power values were compared between groups by ANOVA and Tukey post hoc analysis.
luciferase reporter assay and Immunocytochemistry.
The luciferase assays in Fig 2 were performed in 6 well plates using COS7 cells. 0.5 ng Renilla (Promega, Madison, WI) and 25 ng Per1-luciferase reporter (Kume et al., 1999) were mixed with empty pcDNA (to adjust total DNA content), Clock (100 ng) + Bmal1 (100 ng), or Clock + Bmal1 + Cry1HA (10 ng) for each transfection. A second set was prepared at the same time without Cry1 transfection to compare between Cry1 transfection and infection. GFP or CRY adenovirus was infected into the second set 24 hr after the transfection. Cells were harvested 24 hr after the infection and subjected to lysis and reporter reading according to the protocol of Dual-Luciferase Reporter Assay System (Promega, Madison, WI). Immunocytochemistry in COS7, HEK293 and MEFs was done as described previously (Kume et al., 1999) . For Fig 2 and 6, MEFs were fixed 24 hr after viral infection for immunocytochemistry.
Expression of GFP in liver sections
Mice were euthanized 5 days after injection of adenovirus and fixed by cardiac perfusion of 4%
paraformaldehyde. The liver was removed, processed and 30 μm sections were made on a freezing microtome according to the procedure of von Gall et al (von Gall et al., 2003) . The sections were stained with DAPI to visualize nuclei. GFP and DAPI were visualized by a fluorescence microscope. GFP expressing cells were counted from sections derived from several mice. In most sections, more than 80% of DAPI-stained cells expressed GFP.
Injection of adenovirus into mice and tissue collection.
CD1 and C57BL/6 mice were anaesthetized with a ketamine-xylazine mixture, and 100μl of purified adenovirus in 10 mM, pH8.0 Tris containing 3% sucrose was injected into the tail vein by 29G insulin syringe. The mice were kept in LD for 5 days and then moved to DD and sacrificed on the first day in DD. Tissues were collected and frozen immediately on dry ice at the times indicated in the figures. No virus and, Per mutant and control mice were collected on the first day in DD.
Quantitative Real Time RT-PCR:
Total RNA was extracted from the liver and MEFs using TRIzol Reagent according to the manufacturer's protocol (Invitrogen). Total RNA (1µg) was reverse transcribed using Bio-Rad iScript first cDNA synthesize kit. Quantitation of mRNA levels was performed by real-time PCR using an iCycler iQ PCR System (Bio-Rad, USA). Analyses were performed using the standard curve method with β-Actin as the normalizing endogenous control; the following primer sequences used:
Bmal1 sense 5'-GAA TTC GAA AAG AGG CGT CGG GAC-3'
antisense 5'-GGA TCC TGT GTA TGG GTT GGT GGC AC-3' β-Actin sense 5'-ATG GGTCAGAAGGACTCCTATGTGGG-3'
antisense5'-GGCCACACGCAGCTCATTGTAGAAGG-3'
Immunoblotting for SCN samples
Five SCN punches were pooled for each time point and used for the immunoblots. The SCN region was punched out using a 1.25 mm diameter Harris UNI-CORE puncher (Electron Microscopy Sciences, PA, USA) from a ~1 mm coronal section as described previously (Chen et al., 2008) . The SCN samples were run on SDS-PAGE and transferred onto a blot. The blot was exposed to either X-ray films or Typhoon chemiluminescence scanner (Model 9410, GE HealthCare) after ECL treatment (GE HealthCare). (Hall et al., 2000) (20mM HEPES, pH7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA and protease inhibitors) or Hattori et al. (Hattori et al., 1990) (10% glycerol, 10mM HEPES pH 7.6, 100 mM KCl, 3 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 200 mM Ammonium Acetate and protease inhibitors). Our extraction buffer (EB) condition can extract the majority (>90%) of CLOCK and BMAL1 proteins from liver and MEFs. ~5 volumes of EB were used to extract proteins from tissue. "Sup" and "ppt" are supernatant and precipitate, respectively, after homogenization and centrifugation. The ppt was briefly washed with EB before resuspending it in the same volume of 1X sample buffer as the final sup sample. Both samples were bolied for 3 min at 95° C. Equal volumes of sup and ppt samples were loaded onto the gel. 
